ERBB2 TMD/JMD mutants bind pertuzumab

Stable Identifier
R-HSA-9665703
Type
Reaction [binding]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
ERBB2 R678Q is sensitive to pertuzumab (Pahuja et al. 2018).
Literature References
PubMed ID Title Journal Year
30449325 Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations

Antony, A, Khanna-Gupta, A, Singh, A, Pahuja, KB, Kljavin, NM, Bueno, R, Chougule, A, Dutt, A, Phalke, S, Prabhash, K, Gupta, R, Ziai, J, Banavali, SD, Kumar, P, Trivedi, V, Seshagiri, S, Jaiswal, BS, Nguyen, TT, DeGrado, WF, Ramprasad, V, Vargas, D, Senger, K, Chaudhuri, S, Sokol, ES, Trabucco, SE, Patil, V, Joshi, A, Thaker, TM, Noronha, V, Hartmaier, RJ, Durinck, S, Mravic, M, Stawiski, EW, Jura, N

Cancer Cell 2018
Participants
Participates
Normal reaction
Functional status

Gain of function of ERBB2 R678Q:ERBIN:HSP90:CDC37 [plasma membrane]

Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!